Adult participants with metastatic PDAC with KRAS G12D mutation research hub

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination with mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants with KRAS G12D-mutated Metastatic Pancreatic Adenocarcinoma

This study is testing a new medicine called ASP3082 for people with a specific type of advanced pancreatic cancer. It compares ASP3082 plus standard treatment to standard treatment alone, to see if it helps people live longer and feel better.